Clustering algorithms for multi-database mining (MDM) rely on computing $(n^2-n)/2$ pairwise similarities between $n$ multiple databases to generate and evaluate $m\in[1, (n^2-n)/2]$ candidate clusterings in order to select the ideal partitioning which optimizes a predefined goodness measure. However, when these pairwise similarities are distributed around the mean value, the clustering algorithm becomes indecisive when choosing what database pairs are considered eligible to be grouped together. Consequently, a trivial result is produced by putting all the $n$ databases in one cluster or by returning $n$ singleton clusters. To tackle the latter problem, we propose a learning algorithm to reduce the fuzziness in the similarity matrix by minimizing a weighted binary entropy loss function via gradient descent and back-propagation. As a result, the learned model will improve the certainty of the clustering algorithm by correctly identifying the optimal database clusters. Additionally, in contrast to gradient-based clustering algorithms which are sensitive to the choice of the learning rate and require more iterations to converge, we propose a learning-rate-free algorithm to assess the candidate clusterings generated on the fly in a fewer upper-bounded iterations. Through a series of experiments on multiple database samples, we show that our algorithm outperforms the existing clustering algorithms for MDM.

Increasing clinical and preclinical evidences implicate gut microbiome (GM) dysbiosis as a key susceptibility factor for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s diseases (PD). In recent years, neurodegenerative diseases have not been viewed as driven solely by defects in brain, and the role of GM in modulating the central nervous system function via gut-brain axis has attracted considerable interest. Encouraged by GM researches, the next-generation probiotics may lead to tangible impacts on the treatment of neurodegenerative disorders. This review summarizes the current understandings of GM composition and characteristics associated with neurodegenerative diseases, and the demonstrations of molecules from GM affecting neurodegeneration. Particularly, applications of next-generation probiotics such as Clostridium butyricum, Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bacteroides fragilis for remediation of neurodegenerative diseases are discussed.

Although Sugarcane bagasse ash (SCBA) has good cementitious property, previous researchers have primarily aimed to improve the mechanical performance of conventional concrete or cement-based composites. Research is lacking on ultra-high performance concrete (UHPC), especially regarding tensile self-sensing properties. This paper aimed to comprehensively evaluate the SCBA effect on the UHPC’s mechanical, electrical, and tensile self-sensing properties. The results showed that SCBA below the critical incorporation concentration (CIC) improved the UHPC’s mechanical properties compared to steel fibers alone. Furthermore, adding 3.0wt% SCBA remarkably enhanced the UHPC mechanical properties where the compressive, flexural, and tensile strengths increased by 13.1%, 17.4%, and 20.6%, respectively. The SCBA content of 0.3wt% achieved the maximum UHPC electrical resistivity since values smaller or greater than this content decreased the resistivity. The SCBA-enhanced UHPC showed better tensile stress-sensing performance than UHPC without SCBA due to improved linearity and reversibility, lower hysteresis, higher sensitivity, and superior repeatability. UHPC with 0.3wt% SCBA achieved the best linearity, while UHPC with 0.9wt% SCBA showed the highest sensitivity, lowest hysteresis, and best repeatability. Overall, the content of 0.9wt% SCBA is the best in improving the overall mechanical, electrical, and tensile self-sensing performance.

Extracellular vesicles (EVs) hold enormous potential in the diagnosis and treatment of diseases, benefit from their roles in intercellular signaling, as well as their plentiful presence and stability in body fluids. However, conventional EV isolation methods are labor-intensive, and harvest EVs with low purity and compromised recovery. In addition, the drawbacks, such as limited sensitivity and specificity of traditional EV analysis methods hinder the application of EVs in clinical use. Therefore, it is urgent to develop effective and standardized methods for isolating and detecting EVs. Microfluidics technology is a powerful and rapidly developing technology that has been introduced as a potential solution for the above bottlenecks. It holds the advantages of high integration, short analysis time, low consumption of samples and reagents. In this review, we summarize the traditional techniques alongside microfluidic-based methodologies for the isolation and detection of EVs. We emphasize the separation advantages of microfluidic technology in enhancing EV capture efficiency and precise targeting, while summarizing its analytical role in targeted detection and discussing the significance of EV detection in the tumor microenvironment, providing a direction for achieving automated and high-throughput EV detection in clinical samples.